Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Arch Pharm (Weinheim). 2024 Nov;357(11):e2400410. doi: 10.1002/ardp.202400410. Epub 2024 Aug 23.
Psoriasis is a skin disorder characterized by impaired epidermal differentiation that is regularly treated by systemic drugs with undesirable side effects. Based on its anti-inflammatory, antiproliferative and anti-melanoma attributes, the fungal metabolite kojic acid represents an attractive candidate for anti-psoriatic research. The present work aims to investigate an efficient topical bio-friendly vesicular system loaded with kojic acid isolated from Aspergillus oryzae as an alternative way for the management of psoriasis to avoid systemic toxicity. Kojic acid-loaded spanlastics were prepared by ethanol injection technique, employing span 60 along with brij 35 and cremophor rh40 as edge activators, with the complete in vitro characterization of the developed nanoplatform. The selected formulation displayed a spherical morphology, an optimum particle size of 234.2 ± 1.65 nm, high entrapment efficiency (87.4% ± 0.84%) and significant sustained drug release compared with the drug solution. In vivo studies highlighted the superior relief of psoriasis symptoms and the ability to maintain healthy skin with the least changes in mRNA expression of inflammatory cytokines, achieved by the developed nanoplatform compared to kojic acid solution. Moreover, the in vivo histopathological studies confirmed the safety of the topically applied spanlastics. In addition, the molecular mechanism was approached through in vitro assessment of cathepsin S and PDE-4 inhibitory activities and in silico investigation of kojic acid docking in several anti-psoriatic drug targets. Our results suggest that a topically applied vesicular system loaded with kojic acid could lead to an expansion in the dermo-cosmetic use of kojic acid as a natural bio-friendly alternative for systemic anti-psoriatic drugs.
银屑病是一种皮肤疾病,其特征是表皮分化受损,通常采用具有不良副作用的系统性药物进行治疗。基于其抗炎、抗增殖和抗黑色素瘤的特性,真菌代谢产物曲酸代表了一种有吸引力的抗银屑病研究候选物。本工作旨在研究一种有效的局部生物友好型脂质体系统,该系统负载从米曲霉中分离的曲酸,作为管理银屑病的替代方法,以避免系统毒性。通过乙醇注入技术制备曲酸负载的spanlastics,使用 span 60 以及 brij 35 和 cremophor rh40 作为边缘活性剂,对开发的纳米平台进行全面的体外表征。所选配方显示出球形形态、最佳粒径为 234.2±1.65nm、高包封效率(87.4%±0.84%)和与药物溶液相比显著的持续药物释放。体内研究突出表明,与曲酸溶液相比,开发的纳米平台能够更好地缓解银屑病症状,并能够维持健康的皮肤,炎症细胞因子的 mRNA 表达变化最小。此外,体内组织病理学研究证实了局部应用的 spanlastics 的安全性。此外,通过体外评估组织蛋白酶 S 和 PDE-4 抑制活性以及曲酸在几种抗银屑病药物靶点中的对接进行了计算机模拟研究,探讨了分子机制。我们的结果表明,局部应用负载曲酸的脂质体系统可以扩大曲酸作为天然生物友好型替代系统性抗银屑病药物在皮肤美容中的应用。